Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection
Vinith Yathindranath, Nura Safa, Mateusz Marek Tomczyk, Vernon Dolinsky, Donald W Miller
International Journal of Nanomedicine, doi:10.2147/ijn.s448005
Purpose: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. Methods: Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb). The LNP-Trim consisted of ionizing cationic DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG lipids encapsulating siACE2 or siTMPRSS2. Both formulations were assayed for biocompatibility and cell uptake in airway epithelial cells (Calu-3). Functional assessment of activity was performed using SARS-CoV-2 spike protein binding assays (LNP-Trap), host receptor knockdown (LNP-Trim), and SARS-CoV-2 pseudovirus neutralization assay (LNP-Trap and LNP-Trim). Localization and tissue distribution of fluorescently labeled LNP formulations were assessed in mice following intranasal administration. Results: Both LNP formulations were biocompatible based on cell impedance and MTT cytotoxicity studies in Calu-3 cells at concentrations as high as 1 mg/mL. LNP-Trap formulations were able to bind spike protein and inhibit pseudovirus infection by 90% in Calu-3 cells. LNP-Trim formulations reduced ACE2 and TMPRSS2 at the mRNA (70% reduction) and protein level (50% reduction). The suppression of host targets in Calu-3 cells treated with LNP-Trim resulted in over 90% inhibition of pseudovirus infection. In vivo studies demonstrated substantial retention of LNP-Trap and LNP-Trim in the nasal cavity following nasal administration with minimal systemic exposure. Conclusion: Both LNP-Trap and LNP-Trim formulations were able to safely and effectively inhibit SARS-CoV-2 pseudoviral infection in airway epithelial cells. These studies provide proof-of-principle for a localized treatment approach for SARS-CoV-2 in the upper airway.
Disclosure
References
Ahn, Kim, Hong, Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19, J Clin Investig,
doi:10.1172/JCI148517Arias, Oliveros, Lechtig, Bustos, Biologics in COVID-19 so far: systematic review, Pharmaceuticals,
doi:10.3390/ph15070783Baram-Pinto, Shukla, Gedanken, Sarid, Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles, Small,
doi:10.1002/smll.200902384Bayón-Cordero, Alkorta, Arana, Application of solid lipid nanoparticles to improve the efficiency of anticancer drugs, Nanomaterials,
doi:10.3390/nano9030474Belliveau, Huft, Lin, Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA, Mol Ther Nucleic Acids,
doi:10.1038/mtna.2012.28Bowman, Ballard, Ackerson, Feldheim, Margolis et al., Inhibition of HIV fusion with multivalent gold nanoparticles, J Am Chem Soc,
doi:10.1021/ja710321gChan, Tan, Narayanan, Procko, An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants, Sci Adv,
doi:10.1126/sciadv.abf1738Chen, Cheng, Roffler, Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies, ACS Nano,
doi:10.1021/acsnano.1c05922Chen, Fang, Chen, Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection, ACS Appl Mater Interfaces,
doi:10.1021/acsami.7b09931El-Shennawy, Hoffmann, Dashzeveg, Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2, Nat Commun,
doi:10.1038/s41467-021-27893-2Giovane, Rezai, Henderson, Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: a review, Rev Med Virol,
doi:10.1002/rmv.2136Gong, -J Y, PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo, Eur J Pharmacol,
doi:10.1016/j.ejphar.2010.12.004Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.0202Hak, Helgesen, Hektoen, The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging, ACS Nano,
doi:10.1021/nn301630nHan, Penn-Nicholson, Cho, Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor, International Journal of Nanomedicine,
doi:10.1016/j.virol.2006.01.029Haschke, Schuster, Poglitsch, Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects, Clin Pharmacokinet,
doi:10.1007/s40262-013-0072-7Hoffmann, Hofmann-Winkler, Smith, Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity, EBioMedicine,
doi:10.1016/j.ebiom.2021.103255Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell,
doi:10.1016/j.cell.2020.02.052Huang, Leobandung, Foss, Peppas, Molecular aspects of muco-and bioadhesion: tethered structures and site-specific surfaces, J Control Release,
doi:10.1016/S0168-3659(99)00233-3Kuba, Yamaguchi, Penninger, Angiotensin-Converting Enzyme 2 (ACE2) in the pathogenesis of ARDS in COVID-19, Front Immunol,
doi:10.3389/fimmu.2021.732690Martinez-Avila, Hijazi, Marradi, Gold manno-glyconanoparticies: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN, Chem Eur J,
doi:10.1002/chem.200900923Mesias, Zhu, Tang, Effective ACE2 peptide-nanoparticle conjugation and its binding with the SARS-Cov-2 RBD quantified by dynamic light scattering, Chem Comm,
doi:10.1039/D1CC02267ANathan, Shawa, De, Torre, A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2, Infect Dis Ther,
doi:10.1007/s40121-021-00515-6Nikiforuk, Kuchinski, Twa, The contrasting role of nasopharyngeal angiotensin converting enzyme 2 (ACE2) transcription in SARS-CoV-2 infection: a cross-sectional study of people tested for COVID-19 in British Columbia, Canada, International Journal of Nanomedicine,
doi:10.1016/j.ebiom.2021.103316Papp, Sieben, Ludwig, Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles, Small,
doi:10.1002/smll.201001349Politch, Cu-Uvin, Moench, Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): a Phase I randomized trial, PLoS Med,
doi:10.1371/journal.pmed.1003495Pustake, Tambolkar, Giri, Gandhi, SARS, MERS and CoVID-19: an overview and comparison of clinical, laboratory and radiological features, J Family Med Prim Care,
doi:10.4103/jfmpc.jfmpc_839_21Rao, Xia, Xu, Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines, Proc Natl Acad Sci,
doi:10.1073/pnas.2014352117Ren, Wang, Gao, Zhou, Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance, World J Clin Cases,
doi:10.12998/wjcc.v10.i1.1Schütz, Ruiz-Blanco, Münch, Kirchhoff, Sanchez-Garcia et al., Peptide and peptide-based inhibitors of SARS-CoV-2 entry, Adv Drug Deliv Rev,
doi:10.1016/j.addr.2020.11.007Semple, Klimuk, Harasym, Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures, Biochim Biophys Acta,
doi:10.1016/S0005-2736(00)00343-6Serra, Doménech, Peppas, Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems, CAS, SciSearch ® , Current Contents ® /Clinical Medicine, Journal Citation Reports/Science Edition,
doi:10.1016/j.ejpb.2005.10.011Sullivan, Gebo, Shoham, Early outpatient treatment for Covid-19 with convalescent plasma, N Engl J Med,
doi:10.1056/NEJMoa2119657Sungnak, Huang, Bécavin, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes, Nat Med,
doi:10.1038/s41591-020-0868-6Tam, Kulkarni, An, Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways, Eur J Pharm Sci,
doi:10.1016/j.ejps.2022.106234V'kovski, Kratzel, Steiner, Stalder, Thiel, Coronavirus biology and replication: implications for SARS-CoV-2, Nat Rev Microbiol,
doi:10.1038/s41579-020-00468-6Valenti, Antonini, Lactoferrin: an important host defence against microbial and viral attack. Cellular and molecular life sciences, Cell Mol Life Sci,
doi:10.1007/s00018-005-5372-0Van Der Meel, Chen, Zaifman, Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery, Small,
doi:10.1002/smll.202103025Wotring, Fursmidt, Ward, Sexton, Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern, J Dairy Sci,
doi:10.3168/jds.2021-21247Xu, Ensign, Boylan, Impact of Surface Polyethylene Glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo, ACS Nano,
doi:10.1021/acsnano.5b03876Yathindranath, Safa, Sajesh, Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)-A potential gene target for selective sensitization of glioblastoma cells using an ionizable lipid nanoparticle to deliver siRNA, Cancers,
doi:10.3390/cancers14215179Álvarez-Viñas, Souto, Flórez-Fernández, Torres, Bandín et al., Antiviral activity of carrageenans and processing implications, Mar Drugs,
doi:10.3390/md19080437{ 'indexed': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T01:40:31Z', 'timestamp': 1711676431908},
'reference-count': 60,
'publisher': 'Informa UK Limited',
'license': [ { 'start': { 'date-parts': [[2024, 3, 1]],
'date-time': '2024-03-01T00:00:00Z',
'timestamp': 1709251200000},
'content-version': 'unspecified',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by-nc/3.0/'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'DOI': '10.2147/ijn.s448005',
'type': 'journal-article',
'created': {'date-parts': [[2024, 3, 28]], 'date-time': '2024-03-28T06:50:15Z', 'timestamp': 1711608615000},
'page': '3087-3108',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection',
'prefix': '10.2147',
'volume': 'Volume 19',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5053-9704',
'authenticated-orcid': True,
'given': 'Vinith',
'family': 'Yathindranath',
'sequence': 'first',
'affiliation': []},
{'given': 'Nura', 'family': 'Safa', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mateusz', 'family': 'Tomczyk', 'sequence': 'additional', 'affiliation': []},
{'given': 'Vernon', 'family': 'Dolinsky', 'sequence': 'additional', 'affiliation': []},
{'given': 'Donald', 'family': 'Miller', 'sequence': 'additional', 'affiliation': []}],
'member': '301',
'published-online': {'date-parts': [[2024, 3]]},
'reference': [ { 'key': 'ref1',
'unstructured': 'Available from: https://covid19.who.int/. Accessed March 7, 2023. WHO '
'COVID-19 dashboard'},
{ 'key': 'ref2',
'doi-asserted-by': 'publisher',
'first-page': '10',
'DOI': '10.4103/jfmpc.jfmpc_839_21',
'volume': '11',
'author': 'Pustake',
'year': '2022',
'journal-title': 'J Family Med Prim Care'},
{ 'key': 'ref3',
'doi-asserted-by': 'publisher',
'first-page': '1',
'DOI': '10.12998/wjcc.v10.i1.1',
'volume': '10',
'author': 'Ren',
'year': '2022',
'journal-title': 'World J Clin Cases'},
{ 'key': 'ref4',
'doi-asserted-by': 'publisher',
'first-page': 'e2136',
'DOI': '10.1002/rmv.2136',
'volume': '30',
'author': 'Giovane',
'year': '2020',
'journal-title': 'Rev Med Virol'},
{ 'key': 'ref5',
'doi-asserted-by': 'publisher',
'first-page': '271',
'DOI': '10.1016/j.cell.2020.02.052',
'volume': '181',
'author': 'Hoffmann',
'year': '2020',
'journal-title': 'Cell'},
{ 'key': 'ref6',
'doi-asserted-by': 'publisher',
'first-page': '783',
'DOI': '10.3390/ph15070783',
'volume': '15',
'author': 'Arias',
'year': '2022',
'journal-title': 'Pharmaceuticals'},
{ 'key': 'ref7',
'doi-asserted-by': 'publisher',
'first-page': '6',
'DOI': '10.1186/s40001-021-00626-3',
'volume': '27',
'author': 'Niknam',
'year': '2022',
'journal-title': 'Eur J Med Res'},
{ 'key': 'ref8',
'doi-asserted-by': 'publisher',
'first-page': '23',
'DOI': '10.1186/s12985-023-01973-9',
'volume': '20',
'author': 'Panahi',
'year': '2023',
'journal-title': 'Virol J'},
{ 'key': 'ref9',
'doi-asserted-by': 'publisher',
'first-page': '1700',
'DOI': '10.1056/NEJMoa2119657',
'volume': '386',
'author': 'Sullivan',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref10',
'doi-asserted-by': 'publisher',
'first-page': '632',
'DOI': '10.1001/jama.2021.0202',
'volume': '325',
'author': 'Gottlieb',
'year': '2021',
'journal-title': 'JAMA'},
{ 'key': 'ref11',
'doi-asserted-by': 'publisher',
'first-page': '685',
'DOI': '10.1038/s41579-021-00630-8',
'volume': '19',
'author': 'Yang',
'year': '2021',
'journal-title': 'Nat Rev Microbiol'},
{ 'key': 'ref12',
'doi-asserted-by': 'publisher',
'first-page': '155',
'DOI': '10.1038/s41579-020-00468-6',
'volume': '19',
'author': 'V’kovski',
'year': '2021',
'journal-title': 'Nat Rev Microbiol'},
{ 'key': 'ref13',
'doi-asserted-by': 'publisher',
'first-page': '2603',
'DOI': '10.1056/NEJMoa2034577',
'volume': '383',
'author': 'Polack',
'year': '2020',
'journal-title': 'N Engl J Med'},
{ 'key': 'ref14',
'doi-asserted-by': 'publisher',
'first-page': '712122',
'DOI': '10.3389/fimmu.2021.712122',
'volume': '12',
'author': 'Walsh',
'year': '2021',
'journal-title': 'Front Immunol'},
{ 'key': 'ref15',
'doi-asserted-by': 'publisher',
'first-page': 'e1003495',
'DOI': '10.1371/journal.pmed.1003495',
'volume': '18',
'author': 'Politch',
'year': '2021',
'journal-title': 'PLoS Med'},
{ 'key': 'ref16',
'doi-asserted-by': 'publisher',
'first-page': '375',
'DOI': '10.1038/s41586-022-04797-9',
'volume': '606',
'author': 'Sneller',
'year': '2022',
'journal-title': 'Nature'},
{ 'key': 'ref17',
'doi-asserted-by': 'publisher',
'first-page': 'Cd013825',
'DOI': '10.1002/14651858.CD013825.pub2',
'volume': '9',
'author': 'Kreuzberger',
'year': '2021',
'journal-title': 'Cochrane Database Syst Rev'},
{ 'key': 'ref18',
'doi-asserted-by': 'publisher',
'first-page': '1933',
'DOI': '10.1007/s40121-021-00515-6',
'volume': '10',
'author': 'Nathan',
'year': '2021',
'journal-title': 'Infect Dis Ther'},
{ 'key': 'ref19',
'doi-asserted-by': 'publisher',
'first-page': '276',
'DOI': '10.1038/s41586-021-03777-9',
'volume': '596',
'author': 'Planas',
'year': '2021',
'journal-title': 'Nature'},
{ 'key': 'ref20',
'doi-asserted-by': 'publisher',
'first-page': 'eabf1738',
'DOI': '10.1126/sciadv.abf1738',
'volume': '7',
'author': 'Chan',
'year': '2021',
'journal-title': 'Sci Adv'},
{ 'key': 'ref21',
'doi-asserted-by': 'publisher',
'first-page': '732690',
'DOI': '10.3389/fimmu.2021.732690',
'volume': '12',
'author': 'Kuba',
'year': '2021',
'journal-title': 'Front Immunol'},
{ 'key': 'ref22',
'doi-asserted-by': 'publisher',
'first-page': '15',
'DOI': '10.1016/j.virol.2006.01.029',
'volume': '350',
'author': 'Han',
'year': '2006',
'journal-title': 'Virology'},
{ 'key': 'ref23',
'doi-asserted-by': 'publisher',
'first-page': '47',
'DOI': '10.1016/j.addr.2020.11.007',
'volume': '167',
'author': 'Schütz',
'year': '2020',
'journal-title': 'Adv Drug Deliv Rev'},
{ 'key': 'ref24',
'doi-asserted-by': 'publisher',
'first-page': '783',
'DOI': '10.1007/s40262-013-0072-7',
'volume': '52',
'author': 'Haschke',
'year': '2013',
'journal-title': 'Clin Pharmacokinet'},
{ 'key': 'ref25',
'doi-asserted-by': 'publisher',
'first-page': '3802',
'DOI': '10.1038/s41467-021-24013-y',
'volume': '12',
'author': 'Higuchi',
'year': '2021',
'journal-title': 'Nat Commun'},
{ 'key': 'ref26',
'doi-asserted-by': 'publisher',
'first-page': 'e1802233',
'DOI': '10.1002/adma.201802233',
'volume': '30',
'author': 'Wei',
'year': '2018',
'journal-title': 'Adv Mater'},
{ 'key': 'ref27',
'doi-asserted-by': 'publisher',
'first-page': '27141',
'DOI': '10.1073/pnas.2014352117',
'volume': '117',
'author': 'Rao',
'year': '2020',
'journal-title': 'Proc Natl Acad Sci'},
{ 'key': 'ref28',
'doi-asserted-by': 'publisher',
'first-page': '5165',
'DOI': '10.1038/s41467-020-18880-0',
'volume': '11',
'author': 'Jia',
'year': '2020',
'journal-title': 'Nat Commun'},
{ 'key': 'ref29',
'doi-asserted-by': 'publisher',
'first-page': '148517',
'DOI': '10.1172/JCI148517',
'volume': '131',
'author': 'Ahn',
'year': '2021',
'journal-title': 'J Clin Investig'},
{ 'key': 'ref30',
'doi-asserted-by': 'publisher',
'first-page': '277',
'DOI': '10.1016/0003-2697(74)90034-7',
'volume': '59',
'author': 'Scopes',
'year': '1974',
'journal-title': 'Analy Biochem'},
{ 'key': 'ref31',
'doi-asserted-by': 'publisher',
'first-page': '17',
'DOI': '10.1016/j.ejphar.2010.12.004',
'volume': '654',
'author': 'J-l',
'year': '2011',
'journal-title': 'Eur J Pharmacol'},
{ 'key': 'ref32',
'doi-asserted-by': 'publisher',
'first-page': '5179',
'DOI': '10.3390/cancers14215179',
'volume': '14',
'author': 'Yathindranath',
'year': '2022',
'journal-title': 'Cancers'},
{ 'key': 'ref33',
'doi-asserted-by': 'publisher',
'first-page': '14022',
'DOI': '10.1021/acsnano.1c05922',
'volume': '15',
'author': 'Chen',
'year': '2021',
'journal-title': 'ACS Nano'},
{ 'key': 'ref34',
'doi-asserted-by': 'publisher',
'first-page': '2576',
'DOI': '10.1007/s00018-005-5372-0',
'volume': '62',
'author': 'Valenti',
'year': '2005',
'journal-title': 'Cell Mol Life Sci'},
{ 'key': 'ref35',
'doi-asserted-by': 'publisher',
'first-page': '2791',
'DOI': '10.3168/jds.2021-21247',
'volume': '105',
'author': 'Wotring',
'year': '2022',
'journal-title': 'J Dairy Sci'},
{ 'key': 'ref36',
'doi-asserted-by': 'publisher',
'first-page': '437',
'DOI': '10.3390/md19080437',
'volume': '19',
'author': 'Álvarez-viñas',
'year': '2021',
'journal-title': 'Mar Drugs'},
{ 'key': 'ref37',
'doi-asserted-by': 'publisher',
'first-page': '103255',
'DOI': '10.1016/j.ebiom.2021.103255',
'volume': '65',
'author': 'Hoffmann',
'year': '2021',
'journal-title': 'EBioMedicine'},
{ 'key': 'ref38',
'doi-asserted-by': 'publisher',
'first-page': 'e37',
'DOI': '10.1038/mtna.2012.28',
'volume': '1',
'author': 'Belliveau',
'year': '2012',
'journal-title': 'Mol Ther Nucleic Acids'},
{ 'key': 'ref39',
'doi-asserted-by': 'publisher',
'first-page': '1078',
'DOI': '10.1038/s41578-021-00358-0',
'volume': '6',
'author': 'Hou',
'year': '2021',
'journal-title': 'Nat Rev Mater'},
{ 'key': 'ref40',
'doi-asserted-by': 'publisher',
'first-page': '498',
'DOI': '10.3390/pharmaceutics5030498',
'volume': '5',
'author': 'Tam',
'year': '2013',
'journal-title': 'Pharmaceutics'},
{ 'key': 'ref41',
'doi-asserted-by': 'publisher',
'first-page': '474',
'DOI': '10.3390/nano9030474',
'volume': '9',
'author': 'Bayón-Cordero',
'year': '2019',
'journal-title': 'Nanomaterials'},
{ 'key': 'ref42',
'doi-asserted-by': 'publisher',
'first-page': '2764',
'DOI': '10.1016/j.bbamem.2007.07.008',
'volume': '1768',
'author': 'Zhao',
'year': '2007',
'journal-title': 'Biochim Biophys Acta'},
{ 'key': 'ref43',
'doi-asserted-by': 'publisher',
'first-page': '152',
'DOI': '10.1016/S0005-2736(00)00343-6',
'volume': '1510',
'author': 'Semple',
'year': '2001',
'journal-title': 'Biochim Biophys Acta'},
{ 'key': 'ref44',
'doi-asserted-by': 'publisher',
'first-page': '2103025',
'DOI': '10.1002/smll.202103025',
'volume': '17',
'author': 'van der Meel',
'year': '2021',
'journal-title': 'Small'},
{ 'key': 'ref45',
'doi-asserted-by': 'publisher',
'first-page': '106234',
'DOI': '10.1016/j.ejps.2022.106234',
'volume': '176',
'author': 'Tam',
'year': '2022',
'journal-title': 'Eur J Pharm Sci'},
{ 'key': 'ref46',
'doi-asserted-by': 'publisher',
'first-page': '5648',
'DOI': '10.1021/nn301630n',
'volume': '6',
'author': 'Hak',
'year': '2012',
'journal-title': 'ACS Nano'},
{ 'key': 'ref47',
'doi-asserted-by': 'publisher',
'first-page': '2900',
'DOI': '10.1002/smll.201001349',
'volume': '6',
'author': 'Papp',
'year': '2010',
'journal-title': 'Small'},
{ 'key': 'ref48',
'doi-asserted-by': 'publisher',
'first-page': '9874',
'DOI': '10.1002/chem.200900923',
'volume': '15',
'author': 'Martinez-Avila',
'year': '2009',
'journal-title': 'Chem Eur J'},
{ 'key': 'ref49',
'doi-asserted-by': 'publisher',
'first-page': '1044',
'DOI': '10.1002/smll.200902384',
'volume': '6',
'author': 'Baram-Pinto',
'year': '2010',
'journal-title': 'Small'},
{ 'key': 'ref50',
'doi-asserted-by': 'publisher',
'first-page': '6896',
'DOI': '10.1021/ja710321g',
'volume': '130',
'author': 'Bowman',
'year': '2008',
'journal-title': 'J Am Chem Soc'},
{ 'key': 'ref51',
'doi-asserted-by': 'publisher',
'first-page': '405',
'DOI': '10.1038/s41467-021-27893-2',
'volume': '13',
'author': 'El-Shennawy',
'year': '2022',
'journal-title': 'Nat Commun'},
{ 'key': 'ref52',
'doi-asserted-by': 'publisher',
'first-page': '39953',
'DOI': '10.1021/acsami.7b09931',
'volume': '9',
'author': 'Chen',
'year': '2017',
'journal-title': 'ACS Appl Mater Interfaces'},
{ 'key': 'ref53',
'doi-asserted-by': 'publisher',
'first-page': '6979',
'DOI': '10.1039/D1CC02267A',
'volume': '57',
'author': 'Mesias',
'year': '2021',
'journal-title': 'Chem Comm'},
{ 'key': 'ref54',
'doi-asserted-by': 'publisher',
'first-page': '681',
'DOI': '10.1038/s41591-020-0868-6',
'volume': '26',
'author': 'Sungnak',
'year': '2020',
'journal-title': 'Nat Med'},
{ 'key': 'ref55',
'doi-asserted-by': 'publisher',
'first-page': '103316',
'DOI': '10.1016/j.ebiom.2021.103316',
'volume': '66',
'author': 'Nikiforuk',
'year': '2021',
'journal-title': 'eBioMedicine'},
{ 'key': 'ref56',
'doi-asserted-by': 'publisher',
'first-page': '329',
'DOI': '10.1016/0169-409X(93)90015-V',
'volume': '11',
'author': 'Gizurarson',
'year': '1993',
'journal-title': 'Adv Drug Deliv Rev'},
{ 'key': 'ref57',
'doi-asserted-by': 'publisher',
'first-page': '83',
'DOI': '10.1038/s44222-022-00012-6',
'volume': '1',
'author': 'Cahn',
'year': '2023',
'journal-title': 'Nat Rev Bioeng'},
{ 'key': 'ref58',
'doi-asserted-by': 'publisher',
'first-page': '63',
'DOI': '10.1016/S0168-3659(99)00233-3',
'volume': '65',
'author': 'Huang',
'year': '2000',
'journal-title': 'J Control Release'},
{ 'key': 'ref59',
'doi-asserted-by': 'publisher',
'first-page': '9217',
'DOI': '10.1021/acsnano.5b03876',
'volume': '9',
'author': 'Xu',
'year': '2015',
'journal-title': 'ACS Nano'},
{ 'key': 'ref60',
'doi-asserted-by': 'publisher',
'first-page': '11',
'DOI': '10.1016/j.ejpb.2005.10.011',
'volume': '63',
'author': 'Serra',
'year': '2006',
'journal-title': 'Eur J Pharm Biopharm'}],
'container-title': 'International Journal of Nanomedicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.dovepress.com/getfile.php?fileID=97961',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://www.dovepress.com/getfile.php?fileID=97961',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 3, 28]],
'date-time': '2024-03-28T06:50:22Z',
'timestamp': 1711608622000},
'score': 1,
'resource': { 'primary': { 'URL': 'https://www.dovepress.com/lipid-nanoparticle-based-inhibitors-for-sars-cov-2-host-cell-infection-peer-reviewed-fulltext-article-IJN'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 3]]},
'references-count': 60,
'URL': 'http://dx.doi.org/10.2147/IJN.S448005',
'relation': {},
'ISSN': ['1178-2013'],
'subject': [ 'Organic Chemistry', 'Drug Discovery', 'General Medicine', 'Biomaterials', 'Bioengineering',
'Biophysics', 'Pharmaceutical Science'],
'container-title-short': 'IJN',
'published': {'date-parts': [[2024, 3]]}}
